Physician profile
Stephanie Toll
NPI 1215203948
$15,388.45
in general payments reported to CMS, 2019-2025
9 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.46 · 2021: $17.15 · 2023: $32.50 · 2024: $81.65 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $7,150 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,125 · Consulting Fee: $2,340 · Travel and Lodging: $1,268 · Food and Beverage: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $7,150.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,125.00 |
| Consulting Fee | $2,340.00 |
| Travel and Lodging | $1,268.38 |
| Food and Beverage | $467.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Day One Biopharmaceuticals | $12,743.18 | 2025 | Ojemda |
| Alexion Pharmaceuticals, INC. | $2,389.75 | 2025 | Koselugo |
| Takeda Pharmaceuticals U.S.A., INC. | $110.21 | 2021-2025 | Cuvitru |
| Jazz Pharmaceuticals INC. | $33.02 | 2025 | |
| Uswm, LLC | $28.67 | 2024 | Iwilfin |
| Medunik USA INC. | $23.27 | 2025 | Siklos |
| Y-Mabs Therapeutics, INC. | $22.15 | 2024 | Danyelza |
| Portola Pharmaceuticals, LLC | $20.46 | 2019 | |
| Servier Pharmaceuticals LLC | $17.74 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Toll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.